2024 © Arevuk Advisory Services Pvt Ltd. Coded with from India
Personalis, Inc. is a cancer genomics company, which is engaged in providing precision cancer therapies and diagnostics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. The NeXT platform is a next generation sequencing and analysis platform.
The NeXT platform is designed to provide comprehensive analysis of both a tumor and its immune microenvironment from a single limited tissue or plasma sample. Its products are designed to detect recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Its research-focused products include exome sequencing, transcriptome sequencing, and targeted cancer panels. The Company’s platform analyses elements of the immune cells that have infiltrated a tumor both from the adaptive immune system and the innate immune system. .